The UK’s private GP EHR market is set to grow due to the increasing need for better patient care and various regulations like GDPR, CQC and Information Governance. Demand is also driven by the rise of private GP services, largely due to a scarcity of NHS doctors and the benefits of private care. Markets are segmented by country, with key players including TPP and EMIS Health.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
